Alamar Biosciences is a biotechnology company that is striving to develop a precision proteomics platform that is used in protein biomarker detection. Their flagship technology platform is called NULISA (Nanoparticle Uninhibited Luminescent Immunoassay), and it aims to help researchers detect protein biomarkers down to attomolar concentrations, or extremely small amounts. Alamar Biosciences seeks to use the NULISA platform to increase the speed of development for new diagnostic tests that can detect diseases early and improve treatment options. Alamar Biosciences founded in 2018 and headquartered in Fremont, CA.
Alamar Biosciences is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Alamar Biosciences pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Alamar Biosciences is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
---|---|---|---|---|
2/26/2024 | Series C | $128.27MM raised | $XXX.XX | $XXX.XX |
10/15/2021 | Series B-Plus | $10MM raised | $XXX.XX | $XXX.XX |
9/8/2021 | Series B | $80MM raised | $XXX.XX | $XXX.XX |
5/26/2020 | Series A-1, A-2, A-3 and A-4 | $30.3MM raised | $XXX.XX | $XXX.XX |